Gastrointestinal (GI) Oncology
Comprehensive GI Cancer Care — From Early Detection to Advanced Multimodal Therapy.
Expert surgical, medical, radiation, and interventional oncology for cancers of the esophagus, stomach, pancreas, liver, biliary system, small bowel, colon, and rectum.
The GI Oncology Service provides complete cancer care, including high-ADR screening colonoscopy, advanced endoscopic resection (EMR/ESD), EUS & ERCP staging, cutting-edge imaging (PET-CT, MRI liver protocols), molecular profiling, minimally invasive and robotic surgery, organ-preservation strategies, liver-directed therapies (TACE, Y-90), and state-of-the-art systemic and radiation treatments. Our weekly GI Tumor Board ensures each patient receives a guideline-based, personalized treatment plan.
Common Conditions & Subspecialty Clinics.
- Colon adenocarcinoma
- Rectal cancer
- Anal squamous-cell carcinoma (SCC)
- Hereditary polyposis syndromes (FAP, Lynch)
- Pancreatic ductal adenocarcinoma
- Periampullary cancer
- Cholangiocarcinoma
- Gallbladder cancer
- Esophageal adenocarcinoma and squamous-cell carcinoma
- Gastric cancer
- Gastrointestinal stromal tumor (GIST) of the stomach
- Hepatocellular carcinoma (HCC)
- Fibrolamellar variant of HCC
- Hepatic metastases (e.g., colorectal, breast)
- Neuroendocrine liver metastases
- Gastrointestinal neuroendocrine tumors
- Pancreatic NETs
- Carcinoid syndrome
- Peptide receptor radionuclide therapy (PRRT) and surgical management
- Small-bowel adenocarcinoma
- Appendiceal cancer
- Peritoneal pseudomyxoma
Procedures & Treatments.
-
Total Neoadjuvant Therapy (TNT) and watch-and-wait protocols for rectal preservation
-
Stereotactic Body RT (SBRT) for liver & pancreatic lesions; IMRT for rectal cancer
-
Immunotherapy (PD-1/PD-L1) for MSI-H/dMMR tumors; CTLA-4 + PD-1 combos
-
Targeted therapy—HER2 antibody, FGFR inhibitor, TRK inhibitor, PARP inhibitor
-
mFOLFOX, CAPOX, FOLFIRINOX, gemcitabine-nab-paclitaxel regimens
-
ctDNA minimal residual disease (MRD) testing for relapse prediction
-
PET-CT tracers: ¹⁸F‑FDG, ⁶⁸Ga‑DOTATATE, ¹⁸F‑PSMA for rare NET mets
-
Dual-Energy CT with iodine mapping for pancreatic vascular involvement
-
Liver MRI with gadoxetate & DWI for HCC characterization
-
EUS-FNA/FNB & elastography for pancreatic/biliary masses
-
Colonoscopy with AI-assisted polyp detection; EMR/ESD for T1 lesions
-
Percutaneous Microwave & Irreversible Electroporation (IRE) for pancreatic and liver tumors
-
Y-90 Radioembolization & TACE for unresectable HCC and CRLM
-
HIPEC for peritoneal surface malignancies (oxaliplatin, MMC regimens)
-
Laparoscopic & Robotic Liver Resection, ALPPS, two-stage hepatectomy
-
Robotic Whipple & Distal Pancreatectomy with spleen preservation
-
Robotic Right/Left Colectomy, TaTME, and LAR with fluorescence perfusion
-
Psychosocial oncology, spiritual care, financial counseling
-
Fertility preservation for young adults (sperm & oocyte cryopreservation)
-
Genetic counseling for hereditary GI cancer syndromes (Lynch, FAP)
-
Nutrition & cachexia clinic, exercise oncology, pelvic-floor rehab
Care Pathway & Coordination.
Rapid Referral & Work-up
Colonoscopy/biopsy, imaging, labs completed within 5 days
GI Tumor Board
Consensus plan (surgery, neoadjuvant, systemic, trials)
Treatment Phase
Timely start of therapy; nurse navigator coordinates appointments
Response Assessment
Imaging labs per protocol; ctDNA monitoring
Surgery / Intervention
Minimally invasive resection or liver-directed therapy
Survivorship Follow-up
Surveillance schedule, wellness programs, rapid re-entry for recurrence
Technology & Facilities.
-
4K 3-Chip Laparoscopy & da Vinci Xi Robotics
-
3-T MRI Liver & Pancreas Protocols with AI motion correction
-
Dual-Energy CT & Spectral Imaging
-
Hybrid OR with ICG Fluorescence & Cone-Beam CT
-
Digital Pathology & AI Tumor Grading for rapid margin status
-
Clinical-Trials Unit with Phase I–III GI-Oncology Trials
